ANCA-Associated Vasculitis after Moderna COVID-19 Vaccination.


Journal

Case reports in nephrology
ISSN: 2090-6641
Titre abrégé: Case Rep Nephrol
Pays: United States
ID NLM: 101598418

Informations de publication

Date de publication:
2023
Historique:
received: 07 12 2022
revised: 17 03 2023
accepted: 06 04 2023
medline: 27 4 2023
pubmed: 27 4 2023
entrez: 27 4 2023
Statut: epublish

Résumé

We experienced a case of myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis after Moderna COVID-19 vaccination. An 82-year-old woman developed pyrexia and general malaise one month after her third booster vaccine, and the symptoms persisted. Blood testing revealed inflammation, a high level of MPO-ANCA, and microscopic hematuria. MPO-ANCA-associated vasculitis was diagnosed by renal biopsy. The symptoms improved with steroid therapy. Common adverse reactions to mRNA vaccines against COVID-19 include pyrexia and general malaise, but MPO-ANCA-associated vasculitis can also occur. If pyrexia, prolonged general malaise, urinary occult blood, or renal impairment is observed, the onset of MPO-ANCA-associated vasculitis should be considered.

Identifiants

pubmed: 37101523
doi: 10.1155/2023/4906876
pmc: PMC10125765
doi:

Types de publication

Case Reports

Langues

eng

Pagination

4906876

Informations de copyright

Copyright © 2023 Shiko Gen et al.

Déclaration de conflit d'intérêts

The authors declare that there are no conflicts of interest.

Références

Rheumatol Int. 2021 Aug;41(8):1523-1529
pubmed: 34100115
N Engl J Med. 2022 Mar 17;386(11):1046-1057
pubmed: 35081293
J Clin Rheumatol. 2008 Aug;14(4):243-4
pubmed: 18766128
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Med Sci Monit. 2020 May 05;26:e924700
pubmed: 32366816
Clin J Am Soc Nephrol. 2017 Oct 6;12(10):1680-1691
pubmed: 28842398
J Immunol Res. 2019 May 6;2019:1732175
pubmed: 31198793
Am J Kidney Dis. 2021 Oct;78(4):611-613
pubmed: 34280507
J Korean Med Sci. 2022 Jul 04;37(26):e204
pubmed: 35790206
Kidney Int. 2021 Aug;100(2):473-474
pubmed: 34081948
MMWR Morb Mortal Wkly Rep. 2021 Jan 29;70(4):125-129
pubmed: 33507892
Intern Med. 2005 Aug;44(8):892-6
pubmed: 16157995
Am J Nephrol. 2013;38(2):174-8
pubmed: 23941822
Lancet. 1993 Sep 11;342(8872):651-2
pubmed: 8103148
Rheumatol Int. 2022 Apr;42(4):749-758
pubmed: 35124725
Immunol Rev. 2016 Jan;269(1):60-75
pubmed: 26683145
Kidney Int Rep. 2021 Dec;6(12):2969-2978
pubmed: 34632166
J Exp Med. 2020 Jun 1;217(6):
pubmed: 32302401
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Clin Exp Nephrol. 2022 Apr;26(4):316-322
pubmed: 34773533
Kidney Int. 2021 Nov;100(5):959-965
pubmed: 34534551

Auteurs

Shiko Gen (S)

Department of Nephrology, Saitama Sekishinkai Hospital, Sayama, Japan.

Takanori Iwai (T)

Department of Nephrology, Saitama Sekishinkai Hospital, Sayama, Japan.

Sayuri Ohnari (S)

Department of Nephrology, Saitama Sekishinkai Hospital, Sayama, Japan.

Kanako Nobe (K)

Department of Nephrology, Saitama Sekishinkai Hospital, Sayama, Japan.

Naofumi Ikeda (N)

Department of Nephrology, Saitama Sekishinkai Hospital, Sayama, Japan.

Classifications MeSH